Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology-focused biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announces clinical data ...

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept. There were no clinically meaningful differences in visual outcomes when patients with ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Diabetic macular edema is still a very ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Clearside Biomedical, Inc. announced that the Chinese Center for Drug Evaluation has accepted Arctic Vision's New Drug Application (NDA) for ARCATUS®, a treatment for uveitic macular edema (UME), for ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Sunir J. Garg, MD, shares his recent experience at the American Academy of Ophthalmology Annual Meeting in San Francisco and highlights two key takeaways. First, Dr Garg explores the ...

Diabetic eye disease is a leading cause of vision loss in individuals aged 20 to 74,(3) and diabetic macular edema (DME), left untreated, is the leading cause of blindness in diabetic patients. The ...